Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Short Term Investments?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1996 - 2021 (26 years)

Short Term Investments is 
$131.6M (1Y -42.2% )

ALXN Stock Price & Short Term Investments

Short Term Investments for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Short Term Investments

chevron_right 2021 $34.9M +2.8x
( +5.3% / year avg)
chevron_left 1996 $9.2M
vertical_align_top Peak $4.0B +436x
vertical_align_bottom Bottom $9.2M
arrow_drop_up # Up Years 13 13 of 26
years up.
arrow_drop_down # Down Years 13
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1996 , or +16.1x faster than it's short term investments over the same period.
  • If ALXN grows it's stock at the same rate as it's short term investments (+5.3%/year) , it's stock price will grow +167% and hit $182.22 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 13 years (0%) it's short term investments were also up.
  • ALXN Historical Short Term Investments Table
    in $ million
    Year Short Term Investments YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $34 -79.2% - -
    4/1/2020 $167 -63.5% - -
    4/1/2019 $458 -83.2% - -
    4/1/2018 $2,724 -7.9% - -
    4/1/2017 $2,957 132.0% - -
    4/1/2016 $1,274 -48.9% - -
    4/1/2015 $2,493 -38.1% - -
    4/1/2014 $4,026 599.9% - -
    4/1/2013 $575 1613.7% - -
    4/1/2012 $33 -82.4% - -
    4/1/2011 $190 17.0% - -
    4/1/2010 $163 149.2% - -
    4/1/2009 $65 35.8% - -
    4/1/2008 $48 -67.2% - -
    4/1/2007 $146 -72.2% - -
    4/1/2006 $528 -24.7% - -
    4/1/2005 $701 0.9% - -
    4/1/2004 $694 -11.8% - -
    4/1/2003 $787 -12.5% - -
    4/1/2002 $900 30.3% - -
    4/1/2001 $690 217.8% - -
    4/1/2000 $217 759.1% - -
    4/1/1999 $25 -3.4% - -
    4/1/1998 $26 4.4% - -
    4/1/1997 $25 172.8% - -
    4/1/1996 $9 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Short-term investments, also known as marketable securities or temporary investments, are those which can easily be converted to cash, typically within 5 years. Many short-term investments are sold or converted to cash after a period of only 3-12 months. Some common examples of short term investments include CDs, money market accounts, high-yield savings accounts, government bonds and Treasury bills. Usually, these investments are high-quality and highly liquid assets or investment vehicles.

    For more detailed definitions, please see Investopedia.